Anticancer Drugs Margetuximab Oncology Pharmacology Physiotherapy


In this article we will discuss Margetuximab (Mechanism of Action)

In this article, we will discuss Margetuximab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Margetuximab-cmkb binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Upon binding to HER2-expressing tumor cells, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and
mediates antibody-dependent cellular cytotoxicity (ADCC). In vitro, the modified Fc region of margetuximab-cmkb increases binding to activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitory Fc receptor FCGR2B (CD32B). These changes lead to greater in vitro ADCC and NK cell activation.


The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of margetuximab-cmkb have not been fully characterized.


Following the approved recommended dosage, the steady-state geometric mean (% CV) Cmax of margetuximab-cmkb is 466 (20%) µg/mL and AUC0-21d is 4120 (21%) µ in patients with HER2-positive relapsed or refractory advanced breast cancer. Margetuximab undergoes both linear and nonlinear elimination. After a single dose, margetuximab-cmkb Cmax and AUC0-21d increase in an approximately dose proportional manner from 10 to 18 mg/kg (0.67 to 1.2 times the approved recommended dose). At the approved recommended dosage, time to steady-state was 2 months, and accumulation ratio was 1.65 based on AUC0-21d. No clinically significant differences in margetuximab-cmkb exposure were observed when infusion time was reduced from 120 minutes to 30 minutes.


Margetuximab-cmkb geometric mean (%CV) steady-state volume of distribution is 5.47 L (22%).


The geometric mean (%CV) terminal half-life of margetuximab-cmkb is 19.2 days (28%) and clearance is 0.22 L/day (24%). Four months after margetuximab-cmkb discontinuation, concentrations decrease to approximately 3% of the steady-state trough serum concentration.


Margetuximab-cmkb is expected to be metabolized into small peptides by catabolic pathways.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.